Clinical Laboratory in California

ResearchDx is a comprehensive diagnostic development and contract research organization (CRO) specializing in in vitro diagnostic (IVD) test development, validation, and commercialization. The company operates three integrated divisions: Contract Services (biomarker discovery, assay development, regulatory filings); Diagnostic Laboratory (CLIA/CAP/ISO 15189 accredited clinical testing under the PacificDx brand); and Diagnostic Manufacturing (ISO 13485:2016 and GMP-compliant kit manufacturing under the CustomDx brand). Core capabilities include custom molecular assay development (PCR, qPCR, ddPCR, NGS, microRNA, protein, flow cytometry, ELISA), analytical and clinical validation, companion diagnostic development, and complete laboratory accreditation consulting. The company is ISO 13485:2016 certified, CLIA approved, CAP accredited, and FDA registered. Recent achievements include FDA 510(k) clearances for GlutenID celiac genetic health risk test and regulatory approvals for companion diagnostics (ProMarkerD for diabetic kidney disease, FibroSIGHT for MASH liver fibrosis detection). ResearchDx serves pharmaceutical companies, diagnostic startups, and established laboratories requiring integrated IVD development from concept through commercialization and contract manufacturing.

Simple HealthKit is a healthcare infrastructure platform that delivers end-to-end solutions for member engagement, health screening programs, and connected care delivery. The company operates CLIA-certified laboratory infrastructure and provides vertically integrated screening services paired with digital patient engagement tools. Their platform serves health plans, biopharma companies, public health agencies, and retail pharmacy partners. Simple HealthKit specializes in closing HEDIS gaps, improving Star Ratings, and launching preventive care programs rapidly—typically deployable within weeks. The platform combines AI-driven digital-first tools with high-touch, at-home screening programs, supporting enrollment, screening workflows, and longitudinal patient engagement. Their enterprise-ready software integrates with existing health systems and provides real-time analytics, participation tracking, and audit-ready reporting. Clients include major health plans, insurers, retailers (Walmart, Amazon, CVS Pharmacy), state health departments, and public health organizations. The company emphasizes clinical accuracy through CLIA-certified lab operations while maintaining consumer-friendly, accessible healthcare experiences.

Genesee Scientific LLC is a US-based distributor of laboratory equipment, consumables, and research supplies serving academic, clinical, and biotech laboratories. The company supplies a comprehensive portfolio of cell culture equipment, liquid handling systems, centrifugation equipment, sample agitation devices, and temperature control instruments from established brands including Poseidon, Benchmark, Eppendorf, Apex Bioresearch, FlyStuff, GenClone, Invictus, Next-Gen, Nutri-Fly, Olympus Plastics, and others. Product categories include cell culture equipment and cultureware, cell media, PCR reagents and consumables, nucleic acid extraction products, transfection reagents, liquid handling and pipette tips, tubes, centrifuges, incubators, drosophila-specific consumables and equipment, chemicals (acids, bases, solvents), gloves (including powder-free nitrile options), lab organization and storage solutions, and glassware. The company emphasizes reliable quality through curated product selection, exceptional cost efficiency via portfolio optimization, lab-centric solutions tailored to individual facility workflows, and support for scientific advancement. Genesee Scientific operates an e-commerce platform with account registration, personalized recommendations, promotional pricing programs, and order fulfillment. The company serves research institutions, academic labs, biotech firms, and clinical laboratories with consumables and equipment support.

ML LifeSciences is a contract manufacturer specializing in custom sterile reagents and media for clinical, diagnostic, biotech, veterinary, and quality control laboratory applications. The company offers terminal sterilization, aseptic fills, universal transport media, and compounded reagents across traditional and emerging formulations. Manufacturing capabilities span the full product lifecycle: raw material sourcing, formulation, sterile manufacturing, and packaging in client-specified containers including syringes, transport vials, tubes, PVC and EVA solution bags, and polycarbonate bottles. The company serves clinicians, researchers, laboratory professionals, and diagnostic laboratories with custom solutions for QC, diagnostic, biotech, and veterinary applications. ML LifeSciences is ISO 9001 certified and maintains compliance with federal and state regulatory agencies, ensuring rigorous manufacturing standards and quality control. The company emphasizes on-time delivery, consistent product quality, and superior value for demanding and time-critical projects.

GenDx is a science-based molecular diagnostics company specializing in HLA typing and transplantation diagnostics. The company develops and markets pre- and post-transplant reagent kits, NGS-based HLA typing solutions, and proprietary laboratory software for clinical diagnostics. Product lines include NGSgo-AmpX (next-generation sequencing HLA typing kits for various gene targets including HLA-DRB1, DQB1, and DPB1) and complementary software platforms known for reliability, intuitive navigation, and rapid analysis. GenDx serves transplant laboratories, biobanks, and research institutions globally, with particular emphasis on user-friendly workflows and technical support. The company offers world-class customer support, educational events, and training programs for end users at all proficiency levels. GenDx appears to operate as part of a larger acquisition ecosystem, as evidenced by recent press releases regarding CareDx's transplant lab product division. The company maintains a strong focus on molecular diagnostics quality, laboratory efficiency, and continuous innovation in companion diagnostics and precision medicine applications.

MEDTOX Diagnostics, Inc. is a point-of-care diagnostic company specializing in rapid immunoassay-based drug screening devices. The company manufactures rapid test cassettes, screening cups, and automated readers for substance abuse testing across clinical, workplace, criminal justice, and hospital settings. Primary product lines include MEDTOX PROFILE® cassettes and MEDTOX EZ-SCREEN® cups for screening up to 11 drugs of abuse with results in minutes, and the MEDTOX Scan® automated reader system for high-throughput, convenient screening. The company also offers a fentanyl test device recently cleared by FDA. MEDTOX serves hospitals, workplace wellness programs, clinical trial sponsors, and criminal justice agencies. As of 2026, the company is transitioning its trade name to Labcorp Point of Care under parent company Labcorp ownership. Products are designed for rapid point-of-care screening and typically achieve results within minutes of sample collection. The company provides training and customer support resources for clinical and administrative users.

BioCheck, Inc. is a leader in value-based diagnostics and data monetization, offering high-quality in vitro diagnostic immunoassay devices. The company manufactures and distributes a comprehensive range of diagnostic products including instruments, antibodies, and ELISA kits designed for clinical and research applications. Following the August 2021 acquisition of DRG International, BioCheck operates a global network with subsidiaries and offices across the USA, Germany, Russia, Poland, and Czech Republic, providing distribution capacity to customers in over 110 countries. The DRG:HYBRiD-XL® is a fully automated analyzer for immunoassays and clinical chemistry. Product lines span diagnostic ELISAs, chemiluminescent assays, and specialized antibodies for applications including diabetes diagnosis, endocrinology, prenatal/neonatal supervision, and thyroid function testing. BioCheck emphasizes value-based diagnostics—delivering cost-effective, evidence-based diagnostic testing to improve patient outcomes and reduce unnecessary testing—alongside healthcare data monetization and shared savings models. The company aligns with well-established diagnostic principles, focusing on accessible, reliable tools for hospitals, clinics, research laboratories, and resource-limited settings.

GeminiBio is a biotechnology company founded in 1985, specializing in cell culture solutions and process liquids for the global biotechnology industry, with applications in cell and gene therapy, biotechnology research, and academic research. Operating from a 57,000 square-foot cGMP manufacturing facility in West Sacramento, California, the company is ISO 13485 certified and FDA registered as a Class 1 Medical Device Manufacturer. GeminiBio produces two core product categories: Cell Culture Solutions (including human serum AB, fetal bovine serum, and other animal sera) and Process Liquid Solutions (custom manufacturing of media, buffers, and high-purity water). The company offers Water for Injection (WFI) quality water, purified water, and custom buffer manufacturing in segregated animal origin-free and animal component facilities. Additionally, GeminiBio provides contract manufacturing and regulatory consulting services, emphasizing quality, transparency, and compliance with cGMP standards to support the discovery, development, and commercial production of transformative biotherapeutics.

Illumina, Inc. is a global leader in DNA sequencing and array-based genomic analysis, providing comprehensive solutions for research, clinical diagnostics, and precision health applications. The company manufactures next-generation sequencing (NGS) platforms ranging from benchtop to production-scale instruments, microarray systems for genetic analysis, and library preparation kits optimized for diverse DNA and RNA workflows. Illumina's product portfolio includes the TruPath Genome solution, Single Cell 3' RNA Prep kits, and associated bioinformatics software for data analysis and insights. The company serves academic research institutions, clinical laboratories, pharmaceutical companies, and healthcare providers globally, enabling applications in cancer research, genetic disease testing, infectious disease surveillance, reproductive health, and precision medicine. Illumina offers 24/7 technical support, comprehensive documentation, training resources, and multiple financing options for instrument acquisition. The company maintains regulatory compliance with FDA clearances and international standards, and provides worldwide distribution through channel partners and direct sales. Corporate headquarters located in San Diego, CA with regional offices and support centers across North America, Europe, Asia-Pacific, and other global markets.

DCN Dx is a contract development and manufacturing organization (CDMO) and contract research organization (CRO) specializing in rapid point-of-care diagnostic tests, particularly lateral flow assays and in vitro diagnostics (IVD). Founded in 2006 and based in Carlsbad, California, DCN Dx operates a 35,000+ sq. ft. ISO 13485- and ISO 9001-compliant facility with advanced development labs including a 6,626 sq. ft. BSL-2 lab, dry room capability, and aseptic manufacturing suites. The company provides end-to-end services spanning contract assay development, custom reader design, consumable and cassette design, contract manufacturing, clinical validation, regulatory consulting, and IVD clinical trial management including trial setup, site development, biostatistics, and data management. DCN Dx also offers prospective biospecimen collection services and hosts training courses on lateral flow technology. Their multidisciplinary team works with diagnostics companies, biotech firms, and government-funded research programs to accelerate development from early-stage assay design through clinical validation and manufacturing scale-up.

Bio SB, Inc. is an FDA-registered and ISO 13485:2016 certified biotechnology manufacturer specializing in research, development, production, and distribution of antibodies and detection systems for molecular pathology. The company offers IVD validated monoclonal antibodies (rabbit and mouse), detection systems (ImmunoDetector, PolyDetector), and in situ hybridization technologies (FISH, CISH) for immunohistochemistry (IHC), immunocytochemistry (ICC), immunofluorescence (IF), and related diagnostic applications. Bio SB also manufactures automated staining equipment (TintoStainer Plus, TintoDetector) and tissue/cell line microarrays for cancer diagnostics, microbiology, immunology, and genetics research. The company serves biomedical laboratories, research institutions, and clinical settings globally, manufactured to FDA QSR 21 CFR Part 820 cGMP and CE IVD standards.

Phamatech, Inc. is a US-based manufacturer and laboratory testing provider specializing in rapid diagnostic devices and comprehensive drug testing solutions. The company manufactures rapid diagnostic tests in-house and operates a SAMHSA- and CAP-Forensic-accredited laboratory—the only such facility in the USA performing DNA-verified urine drug testing. Service offerings include forensic drug testing, clinical drug testing, DNA-verified drug testing (U-VERIFY™), and at-home drug testing products. DNA-verified testing uses forensic analysis to match genetic markers from saliva swabs to genetic markers in urine samples, enabling unobserved remote collection and reducing tampering risks. The company tests for 70+ substances using LC-MS/MS methodology with results delivered within 72 business hours. Products include rapid diagnostic test kits (Quick Screen, EZ Home, Clear Choice) that are FDA-approved and CLIA-waived. Phamatech serves federal and state agencies, corrections departments, healthcare providers, employers, and rehabilitation programs. The laboratory operates a vertically integrated case management system providing clients with kit ordering, fulfillment tracking, and direct access to testing results. Manufacturing and testing confirmation are performed in-house at their San Diego facility, ensuring quality control and regulatory compliance at the highest certification levels including SAMHSA, CAP-Forensic, and CLIA accreditation.

True Diagnostics is a medical diagnostics developer and manufacturer specializing in innovative point-of-care and over-the-counter testing solutions. The company designs and produces diagnostic tests and devices to assist physicians in preventing, diagnosing, and treating various medical conditions. True Diagnostics' core offering is the proprietary TrueDX Cassette Technology, a patented diagnostic platform featuring internal calibration methods for flexible assay development. The TrueDX system includes a sample-handling module, integrated reaction pad with immobilized calibrators and reagents, and QR code functionality for automatic assay type detection and patient identification tracking. The cassette platform is engineered for superior shelf-life stability, simple test procedures, and reliable, cost-effective performance across over-the-counter and point-of-care markets. True Diagnostics manufactures disposable over-the-counter readers featuring LCD displays, internal calibration controls, and customizable assay detection. Their products are distributed commercially through major U.S. retailers including Walgreens and Rite Aid. The company operates as a one-stop assay developer and technology partner for organizations seeking point-of-care diagnostic solutions. True Diagnostics serves self-testing, point-of-care testing, and companion diagnostics markets, positioning itself as a provider of lab-quality results in remote and challenging testing environments.

Aptitude Medical Systems is a deep-tech healthcare company specializing in advanced molecular diagnostic testing platforms that deliver lab-quality results without requiring specialized laboratory infrastructure. Founded in 2011 and based in Goleta, California, the company's flagship Metrix platform enables rapid, accurate infectious disease diagnostics in multiple settings including urgent care centers, physician offices, hospitals, pharmacies, and homes. The FDA-authorized Metrix COVID-19 test provides rapid detection of COVID-19 and flu viruses using saliva or swab samples. The company is expanding its molecular testing portfolio to cover respiratory health, sexual health, and other infectious disease conditions. Aptitude's mission centers on democratizing diagnostics by making molecular-level testing accessible, affordable, and operationally simple for healthcare providers and patients globally, while addressing cost and usability challenges inherent in traditional laboratory-based diagnostics.

Kwell Laboratories is a California-based diagnostics company specializing in rapid test kits for infectious diseases, including COVID-19, Flu, RSV, HIV, and Syphilis. The company serves as the U.S. affiliate of GenBody (Korea), importing FDA-cleared in vitro diagnostic (IVD) products and manufacturing select assays domestically. Kwell collaborates with clinical labs, clinics, nursing facilities, and medical distributors to provide point-of-care and over-the-counter testing solutions that are accessible and affordable nationwide. The company also offers private label and white-label diagnostic test kits for OEM partners and healthcare organizations committed to advancing community health through reliable, innovative diagnostic solutions.

Diener Precision Pumps (DPP) is a custom gear pump and metering pump manufacturer serving medical, laboratory, diagnostic, and industrial markets. The company designs and manufactures precision pumps engineered in the USA with production in Switzerland (Embrach). Core product lines include gear pumps (Silencer, Optima, Extreme, Multistream series) for high-volume fluid transfer and continuous flow applications; metering/dosing pumps (Precision and Dual-Precision series) for micro-dosing in diagnostic and analytical equipment; and variable dispense pumps (Exacta series) for sensitive medical applications. DPP specializes in custom OEM solutions with minimum order volume of 100 units/year. Medical and laboratory applications include hemodialysis and peritoneal dialysis systems, laboratory and clinical diagnostics equipment, disinfection and sterilization systems for surgical instruments, and medical device fluid handling. All pumps are manufactured to tight tolerances, tested 100% pre-shipment, laser-marked for traceability, and feature advanced drive electronics for responsive flow and pressure control. The company operates an R&D facility in Lodi, California with prototype capabilities delivering samples within 2–15 days, and maintains quality certifications including NSF/ANSI 169 certification for food-service applications.

Veracyte is a global molecular diagnostics company specializing in genomic testing for cancer diagnosis, risk stratification, and treatment guidance. Founded in 2006 and headquartered in South San Francisco with operations in Austin, Texas, and Haifa, Israel, the company has impacted over 800,000 patients through its evidence-based portfolio of gene expression and genomic sequencing classifiers. Veracyte's core platform integrates transcriptomics, genomics, AI-assisted bioinformatics, and clinical outcome data to deliver actionable insights for thyroid, prostate, breast, bladder, and lung cancers. Key validated tests include Afirma (thyroid nodule classification), Decipher (prostate and bladder genomic assessment), and Prosigna (breast cancer risk of recurrence). The company's diagnostic innovation engine supports both LDT laboratory developed tests and collaborative R&D with biopharmaceutical partners, backed by >600 peer-reviewed publications and >35 prospective clinical trials.

CTK Biotech, Inc. is a California-based biotechnology company specializing in the development and manufacturing of innovative point-of-care (POC) diagnostic test kits and immunodiagnostic tools for the global in vitro diagnostics (IVD) community. Founded in 1997, CTK manufactures portable, easy-to-use rapid diagnostic tests that enable quick and accurate disease diagnosis in clinical, remote, and underserved settings. The company maintains in-house production of recombinant antigens and antibodies, ensuring product quality and compliance with U.S. cGMP standards and WHO approval. CTK's product portfolio includes rapid tests for influenza A/B, H. pylori, syphilis, dengue, RSV, and HIV, with multiple products achieving CE-IVDR marking. As a wholly-owned affiliate of SSI Diagnostica A/S Group, CTK employs approximately 228 personnel and generates ~$28.2M in annual revenue, serving B2B diagnostics customers worldwide.

Avails Medical, Inc. is an in vitro diagnostics company founded in 2013 by Stanford University alumni and based in Menlo Park, California. The company specializes in rapid, automated antibiotic susceptibility testing (AST) technologies aimed at addressing antimicrobial resistance and improving outcomes for sepsis patients. Their innovative all-electrical biosensor platform streamlines the testing process by eliminating manual culturing steps, allowing for faster pathogen quantification and susceptibility testing directly from human specimens. The flagship product, the eQUANT™ System, is an FDA-cleared electronic biosensor that provides results in approximately 70 minutes, significantly reducing turnaround time for testing common gram-negative bacteria. This system is designed for easy integration into laboratory workflows and supports timely diagnostics, which can lead to better patient outcomes and lower healthcare costs. Each minute of diagnostic delay increases sepsis mortality risk; Avails Medical's rapid AST platform addresses the critical clinical need for accelerated antimicrobial susceptibility identification in blood culture specimens, with documented multicenter validation.

FUJIFILM Biosciences (formerly Irvine Scientific LLC) is a life sciences company specializing in cell culture media, bioprocessing solutions, and bioproduction services. The company develops and manufactures chemically defined and specialty cell culture media platforms designed for biotherapeutic and vaccine production, including solutions for CHO (Chinese Hamster Ovary) cell cultures, HEK293 cell lines, and mesenchymal stem cells (MSCs). Product lines include AdaptPD CHO-MK platform media optimized for monoclonal antibody (mAb) production, PRIME-XV MSC basal media for stem cell expansion, and BalanCD HEK293 perfusion media for AAV and lentiviral vector production. The company also provides bioprocessing and custom media development services, supports cell and gene therapy workflows from preclinical through commercial stages, and offers Oceo Rover, an automated on-demand hydration system for powdered media and buffers. FUJIFILM Biosciences serves biopharmaceutical manufacturers, contract development and manufacturing organizations (CDMOs), and research institutions globally. The company operates manufacturing facilities in the Netherlands (Tilburg) with commitments to sustainability and carbon neutrality. U.S. headquarters is located in Santa Ana, California.

BioGenex Laboratories is a US-based manufacturer of in vitro diagnostic instruments, reagents, and detection kits for immunohistochemistry (IHC), in situ hybridization (ISH), fluorescent in situ hybridization (FISH), and multiplex molecular diagnostics. The company serves pathology laboratories, research institutions, and clinical diagnostics centers globally, with offices in Fremont (CA), India, and China. BioGenex produces a comprehensive portfolio of automated staining instruments (Xmatrx® Elite, i6000™, NanoVip™, Neuvo), detection kits, monoclonal and polyclonal antibodies, ISH and FISH probes, antigen retrieval systems (EZ-RT), and ancillary reagents. Products are designed for tumor diagnosis, biomarker panel testing, and gene expression analysis on formalin-fixed, paraffin-embedded (FFPE) tissue specimens. The company offers sales support, technical support, comprehensive training programs, and field service including on-site installation, maintenance, and troubleshooting. Customer base includes major academic medical centers (Mayo Clinic, Cleveland Clinic, Stanford Healthcare, MD Anderson), national reference laboratories (Quest Diagnostics, LabCorp), and hospital systems. BioGenex maintains rigorous product testing and provides operator manuals, scientific literature, and technical documentation.

IDS CO, LTD is a Japanese laboratory automation manufacturer headquartered in Kumamoto, Japan, specializing in specimen transport and automated sample handling systems for clinical laboratories worldwide. The company designs, manufactures, and maintains integrated specimen delivery and processing solutions that serve laboratories of all sizes and configurations. IDS products are manufactured entirely at the Kumamoto headquarters facility under a unified production system spanning development, design, manufacturing, software, sales, and maintenance—enabling consistent world-class quality control. The company maintains a significant global market share in laboratory automation, particularly in specimen transport system technology. Key product lines include the IDS-CLAS X-1 Series (next-generation specimen transport system), IDS-CLAS 3600 (front-end liquid handling/dispensing device), IDS-CLAS 2800 (front-end liquid handling/dispensing device), and IDS-Hr2 (fully automated urine dispensing system). IDS exhibits regularly at major international clinical laboratory conferences including JACLaS EXPO, ADLM (formerly AACC), and Euro MedLab, indicating strong market presence in Asia, North America, and Europe. The company emphasizes versatility and universal compatibility of its systems across diverse laboratory environments and workflows.

BonRay Bio is a medical device company specializing in male reproductive health diagnostics and solutions. Founded in 2016 and based in Taiwan with US operations, the company develops precision medical equipment and automated solutions addressing male infertility. The company's core expertise centers on sperm analysis and optical diagnostic technology. Product portfolio includes routine sperm testing systems, advanced sperm DNA fragmentation detection equipment, and semen processing/washing devices. BonRay Bio serves reproductive medicine clinics, fertility centers, and andrology laboratories globally. The company has secured FDA clearance and holds CE marking, indicating regulatory compliance for US and European markets. Leadership team comprises professionals with over 10 years of medical device development experience. The company positions itself as a leader in sperm diagnostics and optical technology innovation, addressing the growing global demand for male infertility solutions. Recent activities include participation in major international reproductive medicine conferences (ESHRE, CSRM, Medica) and listing on public markets in Taiwan (December 2024). BonRay Bio's LensHooke product line represents their integrated approach to male reproductive diagnostics.

Silver Lake Research Corporation develops, manufactures, and markets rapid point-of-care diagnostic test kits with proprietary EAP™-derived monoclonal antibodies. Founded in 1992, the company specializes in lateral flow immunoassays that deliver laboratory-grade accuracy and sensitivity in minutes at the point of care. The company operates an ISO 13485-compliant, FDA-registered US manufacturing facility—one of the largest independent automated production lines for lateral flow tests—enabling high-volume production of both proprietary products and contract-manufactured diagnostics. Key product lines include HemoTypeSC (hemoglobin phenotyping for sickle cell disease screening), WaterSafe (drinking water quality testing), and RapidBac (rapid urinary tract infection detection requiring no instrumentation). The company has marketed 150+ products and produced over 15 million test strips globally. Services include custom immunoassay development, bespoke assays for specific instruments, and private-label manufacturing. Silver Lake Research serves clinical laboratories, point-of-care testing environments, and contract manufacturing customers. The company emphasizes tangible innovation in antibody development and manufacturing partnerships, positioning itself as a turnkey solution provider for rapid diagnostic platforms.

ARK Diagnostics Inc is a clinical laboratory diagnostics company specializing in the design, development, and manufacture of in vitro diagnostic immunoassays for therapeutic drug monitoring (TDM) and urine drug testing (UDT). The company develops next-generation homogeneous enzyme immunoassays that are liquid, stable, and ready-to-use, with applications available for automated clinical chemistry systems. ARK's product portfolio spans multiple therapeutic categories: epilepsy antiepileptic drug monitoring (gabapentin, lamotrigine, levetiracetam, topiramate, zonisamide, lacosamide, oxcarbazepine metabolite); cancer chemotherapy monitoring (methotrexate); anti-infective agents (linezolid, voriconazole); urine drug testing for substances including opioids, benzodiazepines, synthetic cannabinoids, ketamine, and ethyl glucuronide; and veterinary applications (cortisol, phenobarbital, progesterone, thyroxine, SDMA, gabapentin, levetiracetam, zonisamide). The company holds CE Mark approvals across multiple product lines and FDA clearances (510(k)) for epilepsy assays, cancer assays, and select UDT assays. Voriconazole II received FDA de novo approval. Several products are in development, including additional opioid assays, benzodiazepine formulations, antiretroviral monitoring, and oral anticoagulant assays. ARK serves clinical laboratories, hospital pathology departments, and forensic testing facilities through direct sales and international distributor networks. The company is ISO and GLP-compliant, with active participation in professional conferences (ADLM, IATDMCT, CAT).

Twist Bioscience Corporation is a US-based synthetic biology company specializing in DNA-based research tools and services. The company operates a proprietary semiconductor-based synthetic DNA manufacturing platform utilizing high-throughput silicon technology for miniaturized chemistry and cost-efficient DNA synthesis. Core product portfolio includes synthetic genes (clonal genes, gene fragments, gene pools, vectors), oligonucleotide pools (cloned and uncloned), next-generation sequencing (NGS) target enrichment solutions, library preparation kits (including TrueAmp Library Prep Kit and PCR-free WGS kits), variant libraries (combinatorial, site saturation, spread-out low diversity), and synthetic controls for infectious disease and liquid biopsy applications. The company also offers comprehensive antibody discovery and development services including in vitro phage display, in vivo discovery using Diversimab technology and humanized transgenic mice, antibody characterization (SPR, developability assessment, functional assays), and optimization services including AI/ML-driven affinity maturation and in silico humanization. Twist Service Lab provides outsourced sequencing services, and the company offers automation solutions and API-based procurement integration. Target markets include academic research, pharmaceutical drug discovery, cancer research, infectious disease research, agricultural biotechnology, and clinical diagnostics. The platform enables researchers to access customizable gene synthesis at varying scales, perform high-confidence genomic screening, and conduct precision variant detection across NGS workflows.

i-SENS is a global biotechnology company headquartered in South Korea and operating in over 110 countries, including the United States and Europe. The company is the market leader in Korea's blood glucose monitoring device market and specializes in blood glucose management systems, continuous glucose monitoring (CGM) systems, in vitro diagnostics (IVD), and veterinary diagnostic solutions. i-SENS manufactures the CareSens line of self-monitoring blood glucose systems, which meets ISO 15197:2013 accuracy standards for hematocrit and interference criteria. The CareSens Air continuous glucose monitoring system is the first domestically produced CGM in Korea with CE certification, providing real-time glucose data and trend analysis for diabetes management. The company's IVD System leverages whole blood-based diagnostic technology for point-of-care testing applications. i-SENS operates with an annual production capacity of 2.1 billion blood glucose test strips, supporting millions of patients globally. The company maintains regulatory compliance with FDA and CE certification standards. Recent partnerships include a transformational collaboration with LifeScan to launch the OneTouch® Continuous Glucose Monitoring System, leveraging i-SENS technology. The company serves healthcare systems, diabetes management clinics, point-of-care diagnostic facilities, and veterinary care providers. i-SENS is committed to advancing diabetes care innovation and expanding access to glucose monitoring solutions worldwide.

Chemtron Biotech, Inc. is a diagnostic manufacturer specializing in in vitro diagnostic (IVD) tests for drugs of abuse screening. The company focuses on developing and distributing high-quality testing products and solutions for clinical laboratory and occupational health markets. Chemtron positions itself as a global leader in the drugs of abuse diagnostic sector, with an ongoing commitment to quality assurance, product innovation, and addressing evolving market needs. The company operates a B2B distribution model, working with distributors and partners to reach end-user laboratories and healthcare facilities. Based in San Diego, California, Chemtron serves the diagnostic testing industry with specialized IVD solutions. The company exhibits a professional approach to product development and market engagement, participating in major industry conferences and trade shows (DATIA, AACC, FIME, SAPAA). Regulatory compliance and quality standards are implicit in their focus on the diagnostic testing sector, though specific certifications are not detailed on the current website. Chemtron's product portfolio emphasizes innovation in substance abuse screening, a critical component of clinical diagnostics, workplace testing, and public health initiatives.

Fellow Health Inc. is a CLIA-certified diagnostic laboratory specializing in mail-in semen analysis and reproductive health testing. The company provides clinical-grade semen analysis, vasectomy post-procedure testing, and sperm cryopreservation services to over 3,000 clinics, including urology and reproductive endocrinology practices. Fellow's proprietary testing methodology has been peer-reviewed and validated to deliver clinically accurate results comparable to fresh samples analyzed within one hour, with turnaround times under 2 business days from specimen receipt. The service addresses compliance barriers in post-vasectomy semen analysis testing, achieving 86% compliance rates—significantly higher than industry standards—by offering patients a convenient, privacy-preserving home-based collection option. Fellow operates a CLIA-certified (#05D2177822) and COLA-accredited (#31245) laboratory and has processed over 225,000 samples. The company conducts peer-reviewed research into male reproductive health factors and seminal fluid diagnostics, publishing in journals including Fertility and Sterility and Journal of Urology. Markets served include high-volume vasectomy providers, urologists, reproductive endocrinologists, and OB/GYNs. The testing platform is designed to reduce clinic call volume related to results communication and improve patient satisfaction (93% reported satisfaction).

Artera is an AI-powered precision oncology company developing multimodal artificial intelligence (MMAI) platforms that analyze digital pathology and clinical data to provide personalized cancer treatment recommendations. The company operates a CLIA-certified laboratory in Jacksonville, Florida, delivering laboratory-developed tests (LDTs) for cancer risk stratification and treatment guidance. ArteraAI Prostate Test, the company's flagship offering, received FDA De Novo Authorization as Software as a Medical Device (SaMD), making it the first and only AI test recommended in NCCN Clinical Practice Guidelines for Prostate Cancer. The test provides risk stratification for early-stage prostate cancer patients and predicts which NCCN Intermediate-risk patients will benefit from short-term androgen-deprivation therapy with radiation. The Prostate Test analyzes existing H&E histopathology slides without additional staining, delivers results within 1–2 days, demonstrates consistent performance across diverse populations, and is covered by Medicare and many commercial insurers. Artera also offers the ArteraAI Breast Cancer Test, providing 5- and 10-year distant metastasis risk assessment for early-stage breast cancer and identifies node-negative patients 50+ years old who may benefit from chemotherapy. The platform has been validated across dozens of large randomized phase III clinical trials. Artera maintains headquarters in Los Altos, California, with clinical laboratory operations in Jacksonville, Florida.

DiaSorin Molecular LLC is a world leader in laboratory diagnostics, specializing in immunodiagnostics and molecular diagnostics. The company develops and manufactures in vitro diagnostic systems for detecting antibodies, antigens, and pathogens in biological specimens. Core product lines include the LIAISON® immunodiagnostic platform for infectious disease detection (tuberculosis, hepatitis, viral infections), Simplexa® molecular assay kits for direct pathogen detection (COVID-19, influenza, RSV, cytomegalovirus, herpes simplex virus), and the LIAISON NES® CLIA-waived rapid molecular test delivering results in approximately 15 minutes. Additional offerings include LIAISON® MeMed BV® for bacterial-viral differentiation, LIAISON® QuantiFERON®-TB Gold Plus II for TB detection, and LIAISON® BRAHMS PCT® for infection triage. The company also operates the Luminex division, providing xMAP® multiplex assay platforms and xMAP INTELLIFLEX® systems for research and clinical diagnostics, along with custom assay design and development services. DiaSorin serves clinical laboratories, hospitals, and research institutions globally. The company maintains regulatory compliance with FDA clearances and CLIA waivers for its diagnostic systems. Manufacturing and service capabilities span immunoassay automation, molecular PCR testing, and multiplex diagnostic platforms.

Quantimetrix Corp. manufactures quality control products and laboratory testing solutions for clinical diagnostics. The company specializes in urinalysis quality control materials, including dipstick controls and liquid urinalysis controls for point-of-care testing (POCT). Product lines include Dipper POCT (liquid urinalysis quality control), DiPSpin (urinalysis dipstick and microscopy control), and Complete-D (25-OH vitamin D control). Quantimetrix also offers LiproPrint, a specialty diagnostic tool, and provides OEM and contract manufacturing services. The company operates an online ordering platform and maintains a Quantrol QC program with peer-to-peer statistical analysis capabilities. Manufacturing includes attention to regulatory compliance, with evidence of lot number, expiration date formatting updates and carbon-neutral electronic instructions for use (eIFU) initiatives. Products are designed for laboratory and point-of-care clinical settings requiring quality assurance in urinalysis and chemistry testing.

Lumos Diagnostics is an ASX-listed developer, manufacturer, and distributor of point-of-care diagnostic technologies that deliver rapid, cost-effective diagnostic test solutions for healthcare professionals. The company specializes in rapid blood-based diagnostic assays and proprietary digital reader platforms that enable real-time assessment and differentiation of medical conditions at the point-of-care. FebriDx® is their flagship product—a rapid fingerstick blood test that aids differentiation between bacterial and non-bacterial infections, supporting clinical decision-making around antibiotic use. The company also offers ViraDx and reader platforms. Beyond proprietary products, Lumos provides comprehensive contract development and manufacturing services including strategic innovation and assay development, product development and manufacturing transfer using Lumos technology platforms, clinical and product validation, and commercial-scale manufacture of test strips and digital readers. Their in-house qualified team supports all stages from concept through commercialization, including medical, quality, and regulatory affairs. The US headquarters is located in Carlsbad, California, with a corporate office in Melbourne, Australia. Lumos serves global markets through qualified clinicians, healthcare systems, and diagnostic product manufacturers seeking custom point-of-care diagnostic solutions.

Cytek Biosciences is a leading cell analysis solutions company specializing in full spectrum flow cytometry instruments and reagents for research applications. The company manufactures and distributes a comprehensive portfolio of flow cytometry systems including the Cytek Aurora Evo, Aurora, Aurora CS, Northern Lights, Orion, and legacy platforms (Amnis ImageStreamX, Guava, NL-CLC). Cytek's core technology—full spectrum flow cytometry (FSP)—enables detection of entire fluorochrome emission spectra, allowing researchers to run multiplex panels of 40+ colors simultaneously without sacrificing data resolution. The company offers proprietary cFluor reagents optimized for spectral cytometry, as well as FSP reagent kits, Tonbo reagents, and partnership reagents from Thermo Fisher Scientific. Cytek provides comprehensive services including instrument training, panel design validation, preventative maintenance contracts (value, premium, and service options), equipment maintenance, IQ/OQ certification, and technical support. The company also offers the Cytek Orion reagent cocktail preparation system for automated panel preparation, and software solutions including Cytek Cloud, SpectroFlo analysis software, and the Spectrum Viewer for fluorochrome selection. Applications span immuno-oncology, infectious disease research, inflammatory disease studies, drug discovery, genomics, and immunoprofiling workflows. Cytek maintains manufacturing and service operations in North America (Fremont CA headquarters, San Diego, Bellevue, Bethesda), Europe (Amsterdam, UK), and Asia-Pacific (Japan, Shanghai, Wuxi, Singapore). The company is recognized for innovation in flow cytometry and was named Company of the Year by Industry Chronicle (2025) and recognized by TIME as a 2026 growth leader.

Aiken Corporation is a Southern California-based laboratory equipment manufacturer founded in 1988. The company manufactures and exports a comprehensive range of general laboratory equipment using domestic and foreign components, serving hospitals and clinical laboratories in over 60 countries. Product lines include autoclaves, centrifuges, incubators, dry ovens, water and oil baths, biological safety cabinets, microscopes, tissue processors, balances, pH meters, conductivity meters, spectrophotometers, pipettes, refrigerators, and water purification systems. Additional offerings include microtomes, oscillators, polarimeters, clean benches, ultrasonic water baths, water distillers, and PRP (platelet-rich plasma) processing equipment. Aiken provides customer service Monday–Friday, 8:30 am–5 pm PST, including technical support, field service, maintenance, repair, and troubleshooting. The company emphasizes equipment reliability, operational performance, and total cost reduction for laboratory operations. Distribution is global, with manufacturing networks serving domestic and international markets.

Advin Biotech Inc manufactures FDA-cleared and CLIA-waived drugs of abuse testing products for clinical, workplace, and home use. The company specializes in innovative point-of-care immunoassay formats including urine drug test cups, dipcard assays, and oral fluid tests. Key product innovations include the iSplit Cup (with removable specimen vessel for pristine retention and confirmation testing), POCiT Cup (integrated specimen tube for liquid handler automation), and proprietary 1-second dipcard technology for batch testing efficiency. Product portfolio covers all standard drugs of abuse assays plus specialized tests for EtG, Tramadol, Fentanyl, Ketamine, and the first US FDA-cleared 6AM metabolite test. All tests are customizable for cutoff levels and available for private labeling and co-branding partnerships. The company operates an FDA-registered IVD manufacturing facility in the U.S. with in-house proprietary automated manufacturing processes, ensuring batch-to-batch consistency. Advin Biotech also manufactures COVID-19 antigen tests (EUA-authorized for home use) and oral fluid specimen collection products (SalivaTracer). The company provides on-demand technical support through in-house toxicologists and offers tailored pricing and customization services. Manufacturing and R&D capabilities are conducted domestically with emphasis on quality, speed, and cost efficiency.

Applied Science, Inc. develops regulated medical devices and SaaS platforms serving blood collection and chronic care management markets. The company operates two primary business lines: HemoFlow, an automated whole blood collection system for blood banks, and AdaptivMD, a remote patient monitoring and chronic care management platform. HemoFlow provides mixers, software services, and consumables to optimize transfusion medicine workflows, enabling automated paperless collection, error and waste reduction, enhanced phlebotomist productivity, and centralized device management across blood collection facilities. The platform processes approximately 18 million whole blood donations annually, supporting 54 million transfused blood products globally, with 99.74% customer retention over 13 years. AdaptivMD serves community and rural healthcare providers with value-based care solutions, incorporating remote patient monitoring, telehealth, diabetic retinopathy screening, painless blood glucose monitoring, chronic care management, and EHR-integrated workflows to improve health equity for underserved populations. The company has delivered regulated devices and SaaS services for over 15 years to private and public blood banks worldwide. Applied Science emphasizes interoperability, seamless integrations, and automation efficiencies across its platform portfolio. Service capabilities include passionate, experienced, and agile customer support.

Medical Electronic Systems (MES) is a global leader in semen analysis and sperm quality testing solutions. The company manufactures automated Sperm Quality Analyzers (SQA), laboratory validation kits, and consumer-direct fertility testing products. MES serves fertility clinics, reference laboratories, clinical laboratories, mail-in diagnostic programs, and at-home testing markets across the United States and internationally. The product portfolio includes the SQA-Vision and SQA-iOw automated analyzers for clinical laboratory use; QwikCheck validation and SQA supply kits for quality control and calibration; the YO Home Sperm Test for direct-to-consumer at-home semen analysis; and MaleMan lab services for comprehensive semen evaluation. All analyzers are CE-marked and FDA-cleared. The company maintains direct customer support, calibration and validation services, and international distribution capabilities. MES systems are deployed across fertility centers, major health systems (Kaiser Permanente, Sutter Health, UCHealth, NYC Health + Hospitals), reference laboratories (Labcorp, Quest Diagnostics), military installations (US Air Force, US Navy, US Army), and international institutions in France, Germany, Belgium, Canada, and Australia. The company emphasizes reliability, ease of use, reduced turnaround time, standardized reporting, and decreased manual labor requirements for clinical semen analysis workflows.

ReNovo Solutions is a healthcare and life sciences asset management company founded in 2009, specializing in clinical equipment and technology lifecycle management for hospitals, health systems, and research facilities across the United States. The company provides vendor-neutral clinical asset management, biomedical engineering services, cybersecurity risk mitigation, and IT operations support through its proprietary RENOVOLive® CMMS platform. ReNovo's service portfolio includes clinical engineering staffing, capital equipment planning and consulting, lab asset management, lab operations and compliance support, and laboratory relocation services. The company has managed over 2.1 million assets and maintains a 23.4% client retention rate, demonstrating deep expertise in reducing equipment lifecycle costs by 10-20% while improving operational efficiency and patient care delivery.

W.H.P.M., Inc. is a US-based medical diagnostic company specializing in in vitro diagnostic tests and automated reader systems. The company manufactures and distributes a comprehensive portfolio of clinical diagnostic products including drugs of abuse screening tests, fecal occult blood (iFOB) tests, automated FIT (fecal immunochemical) analyzers, fertility diagnostic tests, and harm reduction testing solutions. The flagship Hemosure® Accu-Reader A100 FIT Analyzer provides automated fecal immunochemical testing for colorectal cancer screening. The company also offers the Hemosure Accu-Reader A100 H. pylori fecal antigen test. W.H.P.M. operates with state-of-the-art manufacturing capabilities and emphasizes research, development, and design to deliver competitive diagnostic solutions. The company maintains an active presence in global medical markets, including participation in MEDICA, the world's leading medical trade fair. Beyond direct product sales, W.H.P.M. offers private label and contract manufacturing services for distribution partners, enabling customized diagnostic solutions. The company serves clinical laboratories, diagnostic centers, and healthcare facilities requiring reliable screening and detection capabilities. Products are designed to meet clinical standards for specimen validity and diagnostic accuracy.

Teledyne Analytical Instruments (TAI) manufactures online gas and liquid analyzers, sensors, and custom integrated analysis solutions for industrial process monitoring and quality control. Primary product lines include gas analyzers (oxygen analyzers, thermal conductivity analyzers, hydrocarbon analyzers, trace gas detection) and liquid analyzers (water quality monitoring systems measuring pH, conductivity, resistivity, ORP, dissolved oxygen, specific ions, turbidity, and chlorine dioxide). The company serves petrochemical, refining, power generation, semiconductor, pharmaceutical, food and beverage, and environmental monitoring sectors. TAI offers hazardous area certified solutions compliant with NEC, ATEX, and IECEx standards. Manufacturing and design are ISO 9001 certified. The company provides technical support, field service repair, and system customization. Located in City of Industry, California, TAI operates as a business unit of Teledyne Instruments, Inc., leveraging the broader Teledyne portfolio's manufacturing and distribution capabilities. Product lines emphasize fast-response, drift-free continuous analysis for high-purity gas streams and real-time water quality monitoring in critical applications.

Karl Hammacher GmbH is a 100-year-old family-owned German manufacturer headquartered in Solingen, specializing in precision instruments for dental, orthodontic, and laboratory applications. The company produces high-quality instruments from stainless steel and WIRONIT (premium dental steel) for dentists, dental technicians, orthodontists (KFO), hospitals, and biological, chemical, medical, and technical laboratories. Products are distributed globally and the company holds membership in the Verband der Deutschen Dentalindustrie (VDDI). The manufacturer serves both clinical and laboratory segments with precision-engineered hand instruments and specialty tools meeting professional standards.

Bioneer Corporation is a life-science research supplier headquartered in Oakland, CA, specializing in molecular biology reagents, enzymes, nucleic acid synthesis and preparation kits, and laboratory instruments. The company manufactures and distributes a comprehensive portfolio including DNA/RNA amplification and prep reagents (AccuPrep kits for genomic DNA, mRNA, plant genomic DNA, and universal RNA), DNA/RNA synthesis reagents and phosphoramidites, polymerases and enzymes, oligonucleotides, RNAi products (siRNA and miRNA), gene synthesis services, protein expression and purification reagents, molecular markers and ladders, plastic consumables, and specialized instruments. Bioneer also offers drug target and toxicity identification services (GPScreen) and maintains a yeast genome-wide S. pombe knock-out library for functional genomics research. The company serves academic research institutions, biotechnology firms, pharmaceutical companies, and contract research organizations in North America. Products are supported by technical protocols, material safety data sheets, reference literature, and application notes. Bioneer maintains both US operations in Oakland and international headquarters in Daejeon, South Korea. The company provides customer support via toll-free phone, email, and direct technical assistance for product troubleshooting and applications development.

BioLegend is a biomedical research company specializing in the development and manufacturing of research reagents and antibodies for scientific investigations. The company operates a modern manufacturing facility in San Diego, California, and offers a comprehensive portfolio including monoclonal and polyclonal antibodies, immunoassay solutions, recombinant proteins, magnetic cell separation products, and single-cell proteogenomics reagents. BioLegend serves research institutions, pharmaceutical companies, and clinical laboratories across multiple therapeutic areas including neuroscience, oncology, immunology, stem cell research, and clinical diagnostics. The company has acquired the Covance antibody product portfolio to strengthen its neuroscience offerings and collaborates with leading research organizations such as The Michael J. Fox Foundation for Parkinson's Research and Illumina. BioLegend provides IVD (in vitro diagnostic) reagents and ASR (Analyte Specific Reagent) products for immunohistochemistry, immunophenotyping, and flow cytometry applications. The company emphasizes quality manufacturing, expert technical support, and custom product development services to support precision medicine, oncology, and biomedical discovery.

Shanghai Sun Biotech Co., Ltd. is a global supplier of thrombosis and hemostasis diagnostic solutions. Founded in 2001, the company specializes in the research, development, production, and distribution of coagulation analyzers, diagnostic reagents, and medical consumables for hemostasis and thrombosis testing. The company operates four primary product lines: UR Series (coagulation analyzers), UL Series (lab automation systems), UG Series (compact coagulation analyzers), and UP Series (portable coagulation analyzers). Product portfolio includes over 120 coagulation products and reagents compatible with multiple leading analyzer platforms (SUNBIO, SYSMEX, Werfen, and Stago instruments). Medical consumables span collection tubes, reagent cups, and related supplies. The company serves a global customer base of over 10,000 clients and operates manufacturing facilities exceeding 40,000 square meters. SunBio holds CE product certifications and conducts multi-center clinical studies for coagulation factor assays and hemostasis markers. The company focuses on thrombosis prevention, coagulation monitoring, and hemostasis assessment across clinical laboratory and hospital settings.

Biomiga, Inc. is a San Diego-based biotech research and manufacturing company specializing in nucleic acid extraction, purification, and PCR-based diagnostic products. Core product lines include the MgPure family of automated DNA/RNA extraction kits designed for diverse sample types: pathogenic, blood, saliva, circulating cell-free DNA, and formalin-fixed paraffin-embedded (FFPE) tissue. The company manufactures DNA/RNA size-selection beads offering superior yield (10–20% better than benchmarks) at competitive pricing, with full USA manufacturing and OEM customization capability. MgPure Seq DTR beads support sequencing workflows with >800 bp average reading lengths, available in manual or automated formats compatible with major platforms (Kingfisher Flex, Biomek, Hamilton, and others). Biomiga offers comprehensive real-time PCR detection assays targeting infectious disease panels, including respiratory pathogen panels (RPP), sexually transmitted infections (STI), gastrointestinal pathogens, women's health, wound infection markers, and nail fungal detection. The company also provides customized services for gene synthesis, cell line construction, protein expression, lentivirus packaging, and next-generation sequencing. FDA-registered facility with ISO 9001:2015 certification. All extraction protocols are fully validated for automation on industry-standard platforms. The company emphasizes in-house manufacturing control, 24/7 customer support, and R&D-driven product development.

LetsGetChecked Inc. is a direct-to-consumer and B2B healthcare company specializing in at-home health testing, telehealth consultations, and pharmacy services. The company manufactures and distributes at-home sample collection kits analyzed by its own CLIA-certified, CAP-accredited laboratory. Services include comprehensive health screening panels (cancer screening, women's health, men's health, infectious disease, biometric screening, and gap-in-care solutions), board-certified telehealth consultations via secure messaging, and affiliate pharmacy services for medication fulfillment and support. LetsGetChecked operates an integrated platform combining in-house manufacturing, laboratory analysis, clinical consultation, and pharmacy operations. The company serves both individual consumers and institutional clients including employers, health plans, health systems, and large organizations (Amazon, Denver Health, Humana, Berkshire Hathaway, University of Virginia, and others). Over 10 million kits have been used, with service delivery focused on accessibility, privacy, and convenience. The company is part of Fuze Health, a broader healthcare innovation platform. Regulatory compliance includes CLIA laboratory certification and CAP accreditation for clinical testing operations.

ID-FISH Technology is a clinical laboratory diagnostics supplier specializing in fluorescence in situ hybridization (FISH) and ImmunoBlot testing technologies for the detection of tick-borne diseases and other pathogens. The company has over 15 years of experience developing diagnostic assays using patented FISH and ImmunoBlot methodologies. FISH technology detects and locates specific DNA sequences on chromosomes with greater sensitivity and specificity than traditional Giemsa-stained smear methods. ImmunoBlot tests determine the presence of pathogen-specific antibodies in patient serum or plasma using recombinant antigens, offering superior sensitivity and specificity compared to Western Blot or ELISA assays. The company's product portfolio includes FDA-cleared Lyme ImmunoBlot kits (iDart Lyme IgM and IgG), which feature 26 and 31 Lyme antigen bands respectively—more than competing immunoblot tests—and uniquely detect antibodies to Osp A (P31) and Osp B (P34) antigens. Products are designed for clinical laboratory use and meet FDA clearance requirements. The company serves clinical laboratory markets requiring sensitive, specific diagnostic testing capabilities for infectious disease detection.

BIOPAC Systems, Inc. designs and manufactures modular, integrated life science data acquisition and analysis systems for research, education, and human insights applications. The company specializes in high-fidelity measurement of physiological signals including electrocardiography (ECG), electroencephalography (EEG), electromyography (EMG), electrodermal activity (EDA), blood pressure, impedance cardiography, and specialized measures such as functional near-infrared spectroscopy (fNIRS) and laser Doppler flow. BIOPAC systems operate in laboratory, MRI, and real-world/field environments with both wired and wireless data logging capabilities. The company serves three primary markets: academic research (human and animal studies, neuroscience, cardiology, psychophysiology), educational institutions (undergraduate and graduate teaching labs across multiple disciplines), and commercial/human insights applications (consumer research, neuromarketing, product development). Products include the AcqKnowledge software platform for data acquisition and analysis, modular hardware units, and the Biopac Student Lab System with integrated curriculum. Systems support advanced signal processing including heart rate variability analysis, automated ECG/EEG/EMG analysis, event-related potentials (ERP), and cognitive state assessment. BIOPAC is cited in over 58,600 peer-reviewed studies. The company provides extensive support through technical specialists, knowledge bases, application notes, webinars, hands-on workshops, and user manuals for both proprietary and third-party hardware integration.

Kenlor Industries manufactures liquid quality control products for clinical urinalysis testing. Since 1988, the company has specialized in stabilized liquid urine controls for dipstick and microscopic assays, offering semiquantitative and qualitative testing solutions. Their products provide two levels of quality assurance controls and include values for leukocytes, urobilinogen, bilirubin, glucose, blood, pH, HCG, and are compatible with Siemens urinalysis strips and Chemstrio/Multistick systems. Kenlor supplies major hospital networks, diagnostic laboratories, and medical centers through partnerships with distributors including McKesson, Fisher Scientific, and PSS World Medical.

BIOVICA International AB is a Swedish biotech company specializing in blood-based cancer diagnostics and treatment monitoring. Their flagship product is DiviTum® TKa, a blood test designed to monitor disease progression in solid tumors by measuring circulating tumor cell proliferation markers. The test is positioned for oncology applications, particularly in breast cancer management, to assess treatment efficacy and predict patient response to therapies such as CDK4/6 inhibitors and endocrine therapies. The company has conducted extensive clinical validation with over 4,500 patients enrolled in studies and maintains 28 peer-reviewed publications. DiviTum® TKa serves pharmaceutical companies, oncologists, and cancer patients by providing early indicators of treatment response—potentially within the first weeks of therapy—enabling more informed treatment decisions and disease monitoring. The company engages with major pharmaceutical partners across 32 pharma projects. Clinical evidence comes from leading oncology centers including University of Michigan Rogel Cancer Center and Washington University School of Medicine. The test represents a liquid biopsy approach for precision oncology decision-making.

Diagnostics for the Real World (DRW) develops decentralized point-of-care (POC) molecular diagnostic systems for use in clinical and non-laboratory settings. The company's flagship platform, SAMBA, is a molecular diagnostic machine designed to deliver rapid pathogen detection at the site where patients are seen, enabling prompt clinical intervention. DRW's SAMBA platform performs multiplex molecular testing for respiratory pathogens including COVID-19, Influenza A/B, and RSV. The system is engineered for simplicity and high performance, supporting "one sample, one test" workflows in hospitals, laboratories, and non-laboratory environments. The company has received regulatory approval in multiple markets, including New Zealand, and maintains a distributed network of service partners and distributors globally. DRW emphasizes decentralized testing infrastructure and rapid turnaround diagnostics as core capabilities. The SAMBA II represents a breakthrough in POC molecular diagnostics and has achieved recognition in major institutional collections and exhibitions. The company provides service and training support, maintains open-access testing programs, and publishes clinical evidence. Manufacturing and regulatory credentials are consistent with EU and international diagnostic standards.

IVD Research, Inc. is an ISO 13485 certified contract manufacturer and original equipment manufacturer (OEM) specializing in the development, manufacture, and marketing of in vitro diagnostic (IVD) assays and laboratory solutions. Founded in 1996, the company operates as an FDA Registered Manufacturer under current Good Manufacturing Practices (cGMP). IVD Research develops and manufactures detection assays for global pathogens across multiple diagnostic technologies, serving customers from R&D through full commercialization. The company offers comprehensive contract manufacturing services including custom assay development, process optimization, and turnkey manufacturing solutions tailored to client specifications. Their expertise spans multiple assay formats and detection methodologies for clinical and research applications. IVD Research emphasizes quality management system compliance, regulatory adherence, and custom-tailored solutions designed to meet specific customer requirements rather than one-size-fits-all approaches. The company provides expert technical support and maintains a commitment to delivering consistent, high-quality diagnostic products with accuracy and reliability. Services include partial manufacturing support through complete product development and commercialization assistance.

Aceso Laboratories Inc. is an in-vitro diagnostic (IVD) company established in 2021 and headquartered in Chino, California. The company specializes in the development, manufacturing, and distribution of integrated IVD solutions for clinical laboratory use. Aceso operates an integrated business model encompassing manufacturing, research and development, and direct sales capabilities. The company's product portfolio focuses on reliable and accurate diagnostic testing solutions designed to support patient care and health management. Aceso positions itself as a value-driven provider committed to innovation in diagnostic testing, with emphasis on quality, reliability, and accuracy. The company maintains a dedicated team of industry professionals, including factory-trained sales and service personnel equipped with current diagnostic tools and support systems. Aceso demonstrates commitment to customer satisfaction through prompt response to customer needs and comprehensive after-sales support. The company actively monitors industry trends and regulatory developments to maintain compliance and deliver latest diagnostic advancements. While specific product lines and regulatory certifications are not detailed on the primary website content, the company describes itself as seamlessly integrating manufacturing, R&D, and sales functions to deliver accessible, high-quality IVD solutions. Further details on specific test platforms, FDA clearances, ISO certifications, and product specifications would require access to the Products page or regulatory documentation.

HeyGears is a digital dentistry and 3D printing company specializing in resin-based additive manufacturing systems and materials for dental laboratories, clinics, and consumer applications. The company manufactures and distributes three primary product lines: UltraCraft Dental Series (MMF, A Series, C Series) for dental manufacturing, Reflex Series for broader consumer and industrial 3D printing applications, and specialized materials for dental and functional prototyping. HeyGears offers integrated solutions combining hardware, proprietary resin materials, cloud-based design and workflow software (HeyGears Cloud for dentistry, Blueprint for Reflex), and technical support services. The Dental Series focuses on fixed restorations, dentures (including recent dual-material one-piece solutions), implant components, and orthodontic models. The Reflex Series targets creative studios, engineers, and manufacturers requiring high-precision functional prototypes. Materials include transparency-optimized resins (PAF10 Clear), flexible elastomers (RE80), and specialized dental restorations. HeyGears provides AI-assisted design automation (AI Box) that converts dental scans to 3D-printable models for multiple applications. The company maintains a global presence with offices in China (Guangzhou, Shenzhen, Suzhou, Hangzhou, Foshan) and the United States (Irvine, California). Technical support, knowledge base resources, warranty policies, and integration partnerships with dental lab management software (e.g., GreatLab) are core service components.

Micro Detect, Inc. (MDI) is a medical diagnostic company based in Tustin, California, specializing in the production and distribution of immunodiagnostic testing kits. The company manufactures IgA, IgM, IgG, and IgE serological test kits designed for clinical laboratory use. MDI emphasizes quality assurance, timely delivery, and cost-effective solutions for healthcare providers and laboratories. The company operates with a regulatory consultant (Ph.D. level) and medical consultant (M.D.) on staff, indicating commitment to compliance and clinical standards. Manufacturing and quality control are managed in-house, with dedicated QC/QA management. The company serves clinical diagnostic markets and maintains standard business hours Monday through Friday, 9 a.m. to 5 p.m. PST. Products are designed with ease of use as a key feature, targeting laboratory and clinical settings requiring rapid serological testing capabilities.

Invetech is a design, engineering, and contract manufacturing partner specializing in diagnostic instruments and cell therapy automation solutions. With over 35 years of experience, the company serves life sciences, biotech, and healthcare organizations, offering end-to-end capabilities from concept through commercialization. Core competencies include instrument design and development, contract manufacturing, custom workflow automation for cell therapy applications, and production-scale manufacturing solutions. Invetech supports product development across benchtop and point-of-care (POC) systems through large core laboratory instruments and mid- to high-throughput platforms. The company maintains a library of interchangeable modular subsystems designed to reduce development risk and improve product reliability. Service offerings encompass custom process automation, formulation and fill systems, and configurable automation platforms. Invetech works with diagnostics companies and cell therapy developers to transition technologies from clinical workflows to commercial manufacturing. The company positions itself as an extension of client engineering teams, integrating specialists in engineering, science, design, and program management.

Immuno Concepts, NA Ltd. is a diagnostic assay manufacturer specializing in systemic rheumatic disease detection, founded in 1979. The company pioneered the conversion from rodent tissue to HEp-2 cells for anti-nuclear antibody (ANA) detection and developed HEp-2000®, a patented ANA substrate with enhanced sensitivity for autoantibodies to SS-A/Ro and other connective tissue disease markers. Product lines include indirect fluorescent antibody (IFA) assays, enzyme immunoassay (EIA/ELISA) systems branded as RELISA™, ColorZyme™ chemiluminescent substrates, and automated specimen processing platforms. The company recently achieved FDA clearance for its IgG Anti-nDNA Fluorescent Test System for use with the Image Navigator® automated imaging platform. Immuno Concepts serves clinical laboratories and rheumatology practices with diagnostic reagents and systems for autoimmune disease detection. The company manufactures and distributes diagnostic reagents meeting FDA and international regulatory standards for in vitro diagnostic use.

ImmunoCentrix Corporation is an FDA-registered manufacturer and distributor of in-vitro diagnostic (IVD) devices headquartered in Canoga Park, California. The company specializes in immunodiagnostic and research products across five core technology platforms: Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Immunofluorescence (IFA), Rapid Tests, and Serology assays. Their product portfolio exceeds 100 immunodiagnostic and research products targeting infectious disease, parasitology, and autoimmune disease diagnostics. ImmunoCentrix maintains FDA registration and holds ISO 13485:2016 and ISO 9001:2015 certifications, demonstrating compliance with medical device manufacturing quality and management system standards. The company manufactures products under strict ISO and FDA quality requirements and distributes globally through direct sales and distributor networks. They offer technical support services and competitively priced products designed for clinical laboratories, research institutions, and diagnostic centers. Manufacturing capabilities encompass bulk reagent preparation and quality assurance protocols consistent with IVD device regulatory requirements.